PETALING JAYA: Duopharma Biotech Bhd
’s net profit jumped by nearly 20% year-on-year (y-o-y) to RM30.7mil in the first quarter ended March 31, 2026 (1Q26), led by a stronger ringgit that helped to ease active pharmaceutical ingredient input costs.
The bottomline was also supported by lower operating expenses and net finance cost.
With stronger profits, this raised the earnings per share to 3.19 sen.
The pharmaceutical company’s first-quarter revenue, however, fell by 5.7% y-o-y to RM247.88mil as demand for insulin products normalised to regular levels following a one-off surge in 1Q25.
Nevertheless, Duopharma noted revenue was supported by growth in the private and export segments, driven in part by a strong performance in the consumer healthcare business.
The group did not declare a dividend.
